Neuro startup Tortugas Neurosciences launched with $106 million to develop in-house and licensed therapies targeting brain disorders. The company’s initial pipeline includes oral small molecules licensed for schizophrenia and tinnitus, and it also plans work on medicines intended for focal epilepsy and encephalopathies. Tortugas is led by veterans of Sage Therapeutics, which was acquired last year, and the company said it expects to test its assets in mid-stage trials in the U.S. The funding and early pipeline highlight continued investment into neuroscience drug discovery and translational development, even as broader funding conditions remain selective for therapeutic areas beyond oncology.